Patient Types/Special Populations: Suppressed Switch
The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice
Paula Teichner, PharmD, AAHIVP, Regional Medical Lead
Cabotegravir
The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice
Paula Teichner, PharmD, AAHIVP, Regional Medical Lead
Cabotegravir
Dovato Real World Evidence Video
Dr. Benjamin Young, Head of Global Medical Directors
Dolutegravir Based Regimens
Dovato Real World Evidence Video
Dr. Benjamin Young, Head of Global Medical Directors
Dolutegravir Based Regimens
DTG+3TC: TANGO 96-Week Data
An Update from HIV GLASGOW 2020
Jose Gatell, Senior Global Medical Director
Dolutegravir Based Regimens
DTG+3TC: TANGO 96-Week Data
An Update from HIV GLASGOW 2020
Jose Gatell, Senior Global Medical Director
Dolutegravir Based Regimens
DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator
Dolutegravir Based Regimens
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator
Dolutegravir Based Regimens
TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
Antiretroviral Therapy and Weight Gain
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
Antiretroviral Therapy and Weight Gain
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research
Dolutegravir Based Regimens
DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research
Dolutegravir Based Regimens
DTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
DTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
DTG + 3TC in Virologically Suppressed, Treatment Experienced Patients: TANGO Study
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
DTG + 3TC in Virologically Suppressed, Treatment Experienced Patients: TANGO Study
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
TANGO 96 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
TANGO 96 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Connect with our Medical Experts
Find my ViiV MSL
Easily find the ViiV Medical Science Liaison (MSL) in your area.
Request a Scientific Discussion
Submit a request for additional information from a ViiV Medical Expert.
Talk to a Medical Expert
Connect now with a live ViiV Medical Expert.
Contact Us
Chat Live
Get immediate assistance from a ViiV Healthcare Professional.
Call 1-888-226-8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-332-1088 or www.fda.gov/medwatch